RE:RE:RE:RE:RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A Responding to Fox's question about FTC review of a large ONCY buyout, I do not think such a buy-out would raise any anti-competitive concerns. We do not have any sales at present, so market power for sales in a given indication is not concentrated due to a buyout. The extreme example of a possible anti-competitive concern would be if one or two large companies already owned most of the oncololytic viruses, and one of them decided to buy us. That would concentrate the broad market for oncoviruses.
But in general ONCY has natural competitive advantages that set it apart from other oncoviruses, due to its double stranded rna structure. In that sense, we vastly different and thus not really potentially competitors of other oncoviruses.
So the short answer is no, there should be no concern about FTC intervention over concentration of markets.